Skip to main content

Table 5 Disease activity at 12 months for patients in DAS28 remission at 6 months.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Disease activity at 12 months

BIOL, n (%)

CON, n (%)

   In remission (DAS28 <2.6)

56 (54.9%)

18 (58.1%)

   Low disease activity (DAS28 <3.2)

17 (16.7%)

7 (22.6%)

   Moderate or high disease activity (DAS28 >3.2)

29 (28.4%)

6 (19.4%)

Total

102

31

  1. BIOL, patients treated with biologics; CON, patients receiving conventional DMARD treatment (control group); DAS28, disease activity score based on 28 joint counts.